Brief: Revive Therapeutics Provides Update On FDA Phase 3 Clinical Trial For Bucillamine In COVID-19 With Planned Completion And Emergency Use Authorization Request
26/02/2021 16:08
Feb 26 (Reuters) - Revive Therapeutics Ltd RVV.CD :
* REVIVE THERAPEUTICS PROVIDES UPDATE ON FDA PHASE 3
CLINICAL
TRIAL FOR BUCILLAMINE IN COVID-19 WITH PLANNED COMPLETION AND
EMERGENCY USE AUTHORIZATION REQUEST
* REVIVE THERAPEUTICS- FURTHER TO DSMB REVIEW, AIMS TO
APPROACH
FDA TO OBTAIN AGREEMENT ON FILING EUA FOR BUCILLAMINE TO TREAT
MILD TO MODERATE COVID-19
Source text for Eikon: ID:nGNXbcxxYt
Further company coverage: RVV.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure